CRESCENT BIOPHARMA, INC. Total Liabilities and Equity
CRESCENT BIOPHARMA, INC. (CBIO) had Total Liabilities and Equity of $182.76 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet
us-gaap:LiabilitiesAndStockholdersEquity · last filed 2026-07-30
- 2026-06-30: Liabilities and Equity $182.76M.
- 2026-03-31: Liabilities and Equity $199.13M.
- 2025-12-31: Liabilities and Equity $240.29M.
- 2025-09-30: Liabilities and Equity $138.27M.
| Period end | Liabilities and Equity | Liabilities and Equity as first filed |
|---|---|---|
| 2026-06-30 | $182.76M 10-Q · filed 2026-07-30 | |
| 2026-03-31 | $199.13M 10-Q · filed 2026-04-29 | |
| 2025-12-31 | $240.29M 10-Q · filed 2026-07-30 | |
| 2025-09-30 | $138.27M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $157.43M 10-Q · filed 2025-07-31 | |
| 2025-03-31 | $5.99M 10-Q · filed 2025-05-14 | |
| 2024-12-31 | $35.62M 10-K · filed 2026-02-26 | $11.09M 10-K · filed 2025-02-13 |
| 2024-09-30 | $15.70M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $24.42M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $34.20M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $45.32M 10-K · filed 2025-02-13 | |
| 2023-09-30 | $53.20M 10-Q · filed 2023-11-03 | |
| 2023-06-30 | $61.82M 10-Q · filed 2023-08-02 | |
| 2023-03-31 | $68.92M 10-Q · filed 2023-05-03 | |
| 2022-12-31 | $51.81M 10-K · filed 2024-03-27 | |
| 2022-09-30 | $55.96M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $65.04M 10-Q · filed 2022-08-03 | |
| 2022-03-31 | $81.46M 10-Q · filed 2022-04-28 | |
| 2021-12-31 | $94.35M 10-K · filed 2023-03-29 | |
| 2021-09-30 | $107.94M 10-Q · filed 2021-11-02 | |
| 2021-06-30 | $124.38M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $138.02M 10-Q · filed 2021-05-03 | |
| 2020-12-31 | $142.83M 10-K · filed 2022-03-03 | |
| 2020-09-30 | $150.42M 10-Q · filed 2020-11-06 | |
| 2020-06-30 | $158.35M 10-Q · filed 2020-07-31 | |
| 2020-03-31 | $162.10M 10-Q · filed 2020-05-01 | |
| 2019-12-31 | $167.97M 10-K · filed 2021-03-02 | |
| 2019-09-30 | $180.45M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $192.33M 10-Q · filed 2019-08-01 | |
| 2019-03-31 | $204.44M 10-Q · filed 2019-05-02 | |
| 2018-12-31 | $214.84M 10-K · filed 2020-02-28 | |
| 2018-09-30 | $225.17M 10-Q · filed 2018-11-02 | |
| 2018-06-30 | $235.70M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $247.42M 10-Q · filed 2018-05-03 | |
| 2017-12-31 | $128.58M 10-K · filed 2019-03-06 | |
| 2017-09-30 | $115.82M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $121.62M 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $37.17M 10-Q · filed 2017-05-08 | |
| 2016-12-31 | $42.39M 10-K · filed 2018-03-06 | |
| 2016-09-30 | $48.01M 10-Q · filed 2016-11-04 | |
| 2016-06-30 | $55.77M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $40.70M 10-Q · filed 2016-05-04 | |
| 2015-12-31 | $48.46M 10-K · filed 2017-03-01 | |
| 2015-09-30 | $55.74M 10-Q · filed 2015-11-12 | |
| 2015-06-30 | $62.04M 10-Q · filed 2015-08-06 | |
| 2015-03-31 | $48.46M 10-Q · filed 2015-05-05 | |
| 2014-12-31 | $57.26M 10-K · filed 2016-02-29 | |
| 2014-09-30 | $62.43M 10-Q · filed 2014-10-31 | |
| 2014-06-30 | $67.52M 10-Q · filed 2014-07-31 | |
| 2014-03-31 | $58.06M 10-Q · filed 2014-05-09 | |
| 2013-12-31 | $5.28M 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |